Collegium Pharmaceutical/ US19459J1043 /
4/26/2024 9:59:55 PM | Chg. +0.58 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
36.41USD | +1.60% | 4,720 Turnover: 171,610.87 |
-Bid Size: - | -Ask Size: - | 36.54 | 36.10 |
GlobeNewswire
4/11
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes D...
GlobeNewswire
2/8
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
GlobeNewswire
10/24/2023
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
GlobeNewswire
10/10/2023
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
GlobeNewswire
8/24/2023
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
GlobeNewswire
2/15/2022
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery...
GlobeNewswire
2/14/2022
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages I...
GlobeNewswire
2/14/2022
BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences Internatio...
GlobeNewswire
2/10/2022
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results
GlobeNewswire
12/28/2021
Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation